Insmed (NASDAQ:INSM) Reaches New 12-Month High on Analyst Upgrade

Insmed, Inc. (NASDAQ:INSM) shares hit a new 52-week high during mid-day trading on Thursday after TD Cowen raised their price target on the stock from $154.00 to $193.00. TD Cowen currently has a buy rating on the stock. Insmed traded as high as $150.16 and last traded at $149.78, with a volume of 1074161 shares changing hands. The stock had previously closed at $147.28.

Several other analysts have also recently weighed in on INSM. Guggenheim increased their price target on shares of Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a research note on Monday, September 8th. Wells Fargo & Company upped their price objective on Insmed from $140.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, September 3rd. Stifel Nicolaus raised their target price on Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Morgan Stanley upped their price target on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, The Goldman Sachs Group increased their price target on Insmed from $114.00 to $142.00 and gave the stock a “buy” rating in a report on Wednesday, August 13th. Nineteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.69.

Insiders Place Their Bets

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the firm’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the completion of the transaction, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This trade represents a 67.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the sale, the director owned 262,675 shares in the company, valued at $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 277,332 shares of company stock valued at $33,842,327. Insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Cullen Frost Bankers Inc. lifted its holdings in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 221 shares in the last quarter. ORG Partners LLC boosted its holdings in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank acquired a new position in Insmed during the 2nd quarter worth $28,000. FNY Investment Advisers LLC purchased a new position in shares of Insmed in the 2nd quarter valued at about $33,000. Finally, NBC Securities Inc. acquired a new position in shares of Insmed during the first quarter worth about $49,000.

Insmed Price Performance

The stock’s 50 day moving average is $131.39 and its two-hundred day moving average is $98.41. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock has a market capitalization of $32.30 billion, a PE ratio of -26.76 and a beta of 1.03.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the previous year, the firm posted ($1.94) EPS. The business’s revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.